Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215558 | 0.88 | CNR2 (0.50) | ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL2215283 | 0.87 | CYP19A1 (0.49) | MAPTMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2214355 | 0.86 | KDM4E (0.56) | PTGER4GAAALDH1A1HPGDKDM4E | |
| SCHEMBL2214060 | 0.86 | ALDH1A1 (0.48) | PTGER4MAPTMEN1KMT2AGAA | |
| SCHEMBL27899832 | 0.86 | CNR2 (0.53) | — | |
| SCHEMBL2220108 | 0.85 | MEN1 (0.45) | PTGER4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2214945 | 0.85 | ALDH1A1 (0.50) | PTGER4MAPTMEN1KMT2AGAA | |
| SCHEMBL27899850 | 0.84 | PTGER4 (0.44) | PTGER4MAPTMEN1KMT2AGAA | |
| SCHEMBL2214911 | 0.84 | ALDH1A1 (0.44) | PTGER4MAPTMEN1KMT2AGAA | |
| SCHEMBL29217034 | 0.83 | CCR2 (0.50) | MAPTMEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| EP-2928884-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| CN-104854098-A | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG | 2015-08-19 | — | — | CN | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| CN-102952151-A | 3-position bis-beta-carboline alkali compound, and preparation method, pharmaceutical composition and application thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885MAPT 4657/4885MEN1 4401/4885 |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | PTGER4 1602/4885MAPT 1483/4885MEN1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.